Researchers are hopeful about potential breakthroughs in Alzheimer's treatment and diagnosis, with new medications and diagnostic tools being developed. However, more testing is needed before these tools can be used as stand-alone diagnostic tools. New blood-testing technologies could potentially support Alzheimer's drug development, but they are still in the early stages of development. The Alzheimer's drug pipeline is heating up, with renewed excitement in experimental drugs targeting beta-amyloids and strategies targeting neuroinflammation, protecting brain cells, and reducing vascular contributions to dementia advancing into clinical trials.